Navigation Links
Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Date:3/25/2013

ess for our company, given the significant growth opportunities in this therapeutic area as well as Shire's proven expertise in specialist markets."

The global ophthalmic pharmaceutical market, valued at approximately $13 billion in 2012 with a compound annual growth rate of 4.5 percent, is consistent with Shire's focus on the specialty market. There are approximately 42,000 office-based ophthalmologists, optometrists and retinal specialists in the United States.

Under the terms of agreement, Shire will make an upfront payment of $160 million and SARcode shareholders will be eligible to receive additional undisclosed payments upon achievement of certain clinical, regulatory, and/or commercial milestones. The transaction is expected to close in the second quarter, subject to regulatory approval in the United States, and other customary closing conditions.  

The acquisition of SARcode will introduce a new late-stage phase 3 clinical program to Shire's research and development portfolio. Shire is currently conducting a prioritization review of its portfolio to accommodate this new expenditure in 2013.

Barclays acted as financial advisor to Shire and Davis Polk LLP acted as legal counsel to Shire.  J.P. Morgan Securities LLC acted as financial advisor to SARCode  and Wilson Sonsini Goodrich & Roasati acted as legal counsel to Sarcode.

LIFITEGRAST and its Clinical Development Program

LIFITEGRAST, a small-molecule integrin antagonist, is believed to work by reducing inflammation through binding inhibition of the proteins lymphocyte function - associated antigen 1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1), influencing T-cell activation and cytokine (protein) release. The interaction between these two proteins plays a key role in the chronic inflammation associated with dry eye. T-cells are important components of the i
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
(Date:5/28/2015)... Sunnyvale, Californiaa (PRWEB) May 28, 2015 ... on “ The Changing Landscape of EMR/EHR Clinical Data ... Annual Meeting taking place in Washington, DC on June ... the challenges of integrating EMR/EHR systems with EDC, and ... the opportunities brought by eSource and electronic health records/electronic ...
(Date:5/28/2015)... Minneapolis, MN (PRWEB) May 28, 2015 ... makes it a point to ask his audiences ... of future trends including robotics, solar cells, fuel ... sequencing, 3D printers, advanced battery storage technology, driverless ... assistants, and high-quality but inexpensive online education. ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... and UNION CITY, Calif., June 2 Santen,Pharmaceutical ... the two,companies have entered into a research and ... Asian development and,commercialization of sirolimus for the treatment ... macular degeneration (wet AMD) and,diabetic macular edema (DME). ...
... of All Evaluable Patients in Phase I Study Receiving Combination of, Bavituximab Plus ... ... - 100% of Evaluable Patients to Date in Ongoing Phase II ... or Stable Disease -, CHICAGO and TUSTIN, Calif., June 2 Peregrine,Pharmaceuticals, ...
... 2 SAFC Hitech(TM), a focus,area within SAFC(R), ... SIAL ),today announced the introduction of the OM700, ... to controlled precursor delivery,for larger lot sizes, enabling ... controls., The OM700 offers reliable and very ...
Cached Biology Technology:Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 2Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 3Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 2Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 3Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 4Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 5SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... 19, 2009Scientists say they are forging ahead in developing ... renewable while having a minimal impact on the environment, ... A consensus is emerging that no one technology will ... novel methodologies will contribute to meeting biofuel needs, according ...
... Swiss Institute of Bioinformatics today announced the winners of the ... Award at the 7th annual [BC]2 Basel Computational Biology Conference. ... The winner of the 2009 SIB Young Bioinformatician Award is ... the past four years with the SIB in the Bioinformatics ...
... of Cordell Bank National Marine Sanctuary indicates that the ... is fair to good, but identifies several emerging threats ... as marine debris, ocean acidification and invasive species have ... said Dan Howard, sanctuary superintendent. "This report provides a ...
Cached Biology News:The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3NOAA report finds threats to California's Cordell Bank Marine Sanctuary 2